Clearmind Medicine (CMND) announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder: the first participant has been enrolled and dosed with CMND-100, its proprietary MEAI-based oral drug candidate, at Hadassah-University Medical Center in Jerusalem, Israel. The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco, Director of the Clinical Pharmacology Unit in the Department of Medicine. This site is part of the Company’s multinational Phase I/IIa clinical trial evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with AUD. Recent top-line results from the first cohort and unanimous Data and Safety Monitoring Board recommendation that the clinical trial continue contribute to supporting strong momentum across all active sites.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine announces milestones in Phase I/IIa trial for CMND-100
- Clearmind Medicine files to sell 5.78M common shares for holders
- Clearmind kicks off patient enrollment at Tel Aviv Sourasky Medical Center
- Clearmind says DSMB approves continuation of Phase I/IIa trial of CMND-100
- Psychedelic: Clearmind reports results from first cohort in AUD trial